Last $119.21 USD
Change Today -1.73 / -1.43%
Volume 950.4K
VRX On Other Exchanges
New York
As of 12:02 PM 07/10/14 All times are local (Market data is delayed by at least 15 minutes).

valeant pharmaceuticals inte (VRX) Snapshot

Previous Close
Day High
Day Low
52 Week High
02/27/14 - $153.10
52 Week Low
07/10/13 - $89.27
Market Cap
Average Volume 10 Days
Shares Outstanding
Dividend Yield

valeant pharmaceuticals inte (VRX) Details

Valeant Pharmaceuticals International, Inc. develops, manufactures, and markets pharmaceuticals, over-the-counter (OTC) products, and medical devices in the areas of eye health, dermatology, and neurology therapeutic classes worldwide. Its pharmaceutical products include Solodyn, an oral antibiotic that treats red and pus-filled pimples, as well as Ziana, Acanya, and Atralin; Wellbutrin XL, a formulation used for the treatment of major depressive disorder in adults; Xenazine for the treatment of chorea; Zovirax Cream for herpes labialis; Zovirax ointment for initial genital herpes; The Lotemax gel for post-operative inflammation and pain; Arestin, a subgingival sustained-release antibiotic; and Prolensa, a non-steroidal anti-inflammatory ophthalmic solution. The company also provides OTC products, such as PreserVision, an antioxidant eye vitamin and mineral supplement; ReNu Multiplus, a sterile that is used to lubricate and rewet soft contact lenses; Ocuvite, a lutein eye vitamin and mineral supplement; Artelac, an eye drops to treat dry eyes; and CeraVe products for skin. In addition, it offers device products, including SofLens daily disposable contact lenses; Restylane, an injectable implant dermal fillers; PureVision, a contact lens; Dysport, an injection neurotoxin; ophthalmic surgical products, such as Akreos and Crystalens; surgical equipment comprising the VICTUS femtosecond laser and the Stellaris PC, a vitreoretinal and cataract surgery system; and medical device systems for aesthetic applications. Further, it provides generic products comprising Retin-A Micro, a tretinoin gel; tobramycin and dexamethasone ophthalmic suspensions for steroid responsive inflammatory ocular conditions; and latanoprost to treat glaucoma. The company was formerly known as Biovail Corporation and changed its name to Valeant Pharmaceuticals International, Inc. in September 2010. Valeant Pharmaceuticals International, Inc. was founded in 1983 and is headquartered in Laval, Canada.

17,200 Employees
Last Reported Date: 02/28/14
Founded in 1983

valeant pharmaceuticals inte (VRX) Top Compensated Officers

Chairman and Chief Executive Officer
Total Annual Compensation: $1.8M
Chief Financial Officer, Principal Accounting...
Total Annual Compensation: $1.0M
Chief Legal Officer, Head of Corporate & Busi...
Total Annual Compensation: $750.0K
Executive Vice President and Company Group Ch...
Total Annual Compensation: $511.1K
Total Annual Compensation: $37.9K
Compensation as of Fiscal Year 2013.

valeant pharmaceuticals inte (VRX) Key Developments

Valeant Pharmaceuticals International, Inc. Receives U.S. Food and Drug Administration Clearance for Restylane Silk Injectable Gel with 0.3% Lidocaine

Valeant Pharmaceuticals International, Inc. announced that the U.S. Food and Drug Administration (FDA) has issued marketing clearance for Restylane(R) Silk Injectable Gel with 0.3% Lidocaine, a device indicated for submucosal implantation for lip augmentation and dermal implantation for correction of perioral rhytids in patients over the age of 21. Restylane Silk is a crystal clear injectable gel composed of hyaluronic acid, a natural substance that already exists in the body. Restylane Silk is non-animal based and free from animal protein. Allergy pretesting is not necessary. Restylan Silk contains 0.3% lidocaine, which was added to reduce the discomfort associated with the treatment. Clinical study was conducted with Restylane(R) Silk to evaluate the safety and effectiveness of injections to enhance lip fullness and to improve the wrinkles around the lips. The study included 221 mostly female subjects and evaluated subjects with light and dark skin. Subjects with very dark skin were not studied. 98% of subjects reported improvement in their lip fullness 14 days after injection and 76% of the subjects still had lip improvement 6 months after their injection. The majority of adverse events were mild in intensity and the most common symptoms were lip swelling, contusion, and lip pain. The incidence of adverse event decreased significantly after the second treatment. Restylane Silk is contraindicated for patients with severe allergies manifested by a history of anaphylaxis or history or presence of multiple severe allergies; patients with a history of allergies to gram positive bacterial proteins; patients with bleeding disorders; for implantation in anatomical spaces other than the dermis or submucosal implantation for lip augmentation and should not be used in patients with previous hypersensitivity to local anesthetics of the amide type, such as lidocaine.

Valeant Pharmaceuticals International, Inc. Announces Planned Departure of Ryan Weldon as Executive Vice President and Group Chairman

Valeant Pharmaceuticals International, Inc. (Valeant) announced that Ryan Weldon, Valeant's Executive Vice President and Company Group Chairman, will be leaving the company following the divestiture of all rights to Restylane, Perlane, Emervel, Sculptra, and Dysport owned or held by Valeant to Nestlé S.A. Nestle expects to complete its acquisition of Galderma S.A. in July and would expect to operate the acquired assets through Galderma.

Valeant Pharmaceuticals International, Inc. - Special Call

To discuss recent misleading assertions made by Allergan, Inc. and others


Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
VRX:US $119.21 USD -1.73

VRX Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Actavis plc $214.46 USD -2.82
Astellas Pharma Inc ¥1,339 JPY -13.00
Mylan Inc/PA $50.10 USD +0.04
Shire PLC 4,600 GBp +81.00
Sun Pharmaceutical Industries Ltd 726.25 INR +1.85
View Industry Companies

Industry Analysis


Industry Average

Valuation VRX Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 6.2x
Price/Book 7.9x
Price/Cash Flow 86.9x
TEV/Sales 3.4x

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact VALEANT PHARMACEUTICALS INTE, please visit Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at